Compare EPR Properties (EPR) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

EPR Properties trades at $54.08, down 2.15% on the day, with a bearish technical signal. The REIT maintains strong fundamentals, including a 91.41% gross margin and a 37.66% net income margin, though net income is projected to dip slightly in 2026. Recent news highlights its focus on monthly dividends and diversification beyond theaters into experiential properties.

The outlook is mixed; analyst consensus is a 'Buy' with a $65.50 price target, suggesting significant upside, but technical indicators and a recent earnings miss signal near-term caution. Key risks include exposure to interest rate sensitivity and execution of its diversification strategy amidst a bearish market sentiment.

Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.

The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.